Over the years, immune checkpoint inhibitors (CPIs) have become a powerful treatment
strategy in the field of cancer immunotherapy. In the last decade, the number of FDA …

Patient-based health related quality of life (HRQoL) measurements are associated with an
improvement in quality of care and outcomes. For a complex disease such as sarcoma …

Simple Summary PRESERV MEL (P rospective and RE trospective S tudy of nivolumab th
ER apy in adju V ant MEL anoma) is a real-world observational study evaluating the …

Background Single‐agent immune checkpoint inhibitors (ICIs) have demonstrated limited
responses in recurrent ovarian cancer; however, 30%–40% of patients achieve stable …

Background Access to cancer care is an issue in low and low middle-income countries. The
problem is worse with respect to access to new therapies like checkpoint inhibitors. Hence …

Therapies targeting the PD-1/PD-L1 pathway have transformed head and neck squamous
cell carcinoma (HNSCC) treatment. However, predicting the response to anti-PD-1 therapy …

Immune checkpoint inhibitor (ICI)-related chronic pneumonitis is rare. Limited information is
available on the characteristics of this condition. Herein, we present the case of a 54-year …

With the use of targeting delivery systems, drugs can be specifically administered to tumor
cells based on the abundant expression of cell surface markers with minimal expression in …

With the successive development of chemotherapy drugs, good results have been achieved
in clinical application. However, myocardial toxicity is the biggest challenge. Anthracyclines …

Purpose The efficacy of immunotherapy for non-small cell lung cancer (NSCLC) is limited
owing to cold tumors and drug resistance. Therefore, it is important to identify the molecular …